Olivia Vizier

The future of cancer immunotherapy with Elicio Therapeutics

AMP immunotherapy enhanced the infiltration and function of TCR-T cells in the tumour microenvironment and led to epitope spreading against diverse tumour targets. Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

The future of cancer immunotherapy with Elicio Therapeutics Read More »

New Cancer Vaccines Could Treat Some Types of Pancreatic, Colorectal and Other Deadly Forms of the Disease

The trial included 25 people with pancreatic or colorectal cancer who had previously undergone surgery, seven of whom also had received radiation therapy. They were given up to 10 doses of the vaccine known as ELI-002, and the results were promising: 84 percent of all participants had positive T cell responses—and all of those who

New Cancer Vaccines Could Treat Some Types of Pancreatic, Colorectal and Other Deadly Forms of the Disease Read More »

patient_worthy

Rare Community Profiles: Dr. Pisit “Duke” Pitukcheewanont Discusses Phase 2 Results in LUM-201 for Pediatric Growth Hormone Deficiency

Lumos Pharma is developing LUM-201 (ibutamoren) for the treatment of moderate pediatric growth hormone deficiency. PGHD is a rare disorder in which the body doesn’t make enough growth hormone.

Rare Community Profiles: Dr. Pisit “Duke” Pitukcheewanont Discusses Phase 2 Results in LUM-201 for Pediatric Growth Hormone Deficiency Read More »

Fierce-Biotech

Elicio’s therapeutic cancer vaccine boosts T-cell therapy response in mice while biotech awaits phase 2 data

As Elicio Therapeutics awaits a phase 2 readout of its lymph node-targeting therapeutic cancer vaccine in humans, the biotech has published fresh preclinical data showing the same tech boosted the efficacy of T cell receptor-modified T-cell (TCR-T) therapy in mice.

Elicio’s therapeutic cancer vaccine boosts T-cell therapy response in mice while biotech awaits phase 2 data Read More »

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

Lumos Pharma is dedicated to transforming the treatment landscape for rare pediatric diseases like PGHD. Lumos Pharma’s approach is not just about creating new drugs; it’s about rethinking the entire patient experience, prioritizing ease of use and minimizing the treatment burden on young patients and their families. Their work exemplifies a broader shift in the

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development Read More »

Overcoming Barriers to Adherence in HIV: A Case for an Innovative Approach to Treatment

Innovation in the HIV treatment landscape is playing a role in addressing medication adherence. In recent years, long-acting injectable antiretroviral monthly and bi-monthly treatment options have been approved – a welcome alternative for people living with HIV. We are now on the cusp of it coming full circle from the days when patients took multiple

Overcoming Barriers to Adherence in HIV: A Case for an Innovative Approach to Treatment Read More »

medium_BTN_logo_for_transmission.fm-1

The Next Ozempic or Wegovy… But Without the Injection? Dr. Steffen-Sebastian Bolz, CSO, Aphaia Pharma

What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2.

The Next Ozempic or Wegovy… But Without the Injection? Dr. Steffen-Sebastian Bolz, CSO, Aphaia Pharma Read More »

medium_BTN_logo_for_transmission.fm-1

Everybody Has a Thyroid… What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma

Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

Everybody Has a Thyroid… What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma Read More »